Premium
Carfilzomib, dexamethasone and daratumumab in relapsed or refractory multiple myeloma: results of the phase III study CANDOR by prior lines of therapy
Author(s) -
Quach Hang,
Nooka Ajay,
Samoylova Olga,
Venner Christopher P.,
Kim Kihyun,
Facon Thierry,
Spencer Andrew,
Usmani Saad Z.,
Grosicki Sebastian,
Suzuki Kenshi,
Delimpasi Sosana,
Weisel Katja,
Obreja Mihaela,
ZahltenKumeli Anita,
Mateos MariaVictoria
Publication year - 2021
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.17541
Subject(s) - lenalidomide , daratumumab , carfilzomib , medicine , multiple myeloma , bortezomib , oncology , dexamethasone , proteasome inhibitor , ixazomib